Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.

HFCAS OpenIR

	Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.
	Bachy, Emmanuel ; Savage, Kerry J.; Huang, Huiqiang ; Kwong, Yok-Lam ; Gritti, Giuseppe ; Zhang, Qingyuan ; Liberati, Anna Marina ; Cao, Junning ; Yang, Haiyan ; Hao, Siguo ; Hu, Jianda ; Zhou, Keshu ; Russo, Filomena ; Zhang, Huilai ; Sang, Wei ; Ji, Jie ; Liu, Hui ; Huang, Sha ; Zinzani, Pier Luigi
	2022-06-01
发表期刊	JOURNAL OF CLINICAL ONCOLOGY
ISSN	0732-183X
收录类别	SCI
语种	英语
资助项目	BeiGene USA, Inc.
项目资助者	BeiGene USA, Inc.
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000863680302014
出版者	LIPPINCOTT WILLIAMS & WILKINS
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/129812
专题	中国科学院合肥物质科学研究院
作者单位	1.Lyon Sud Hosp, Hematol Dept, Lyon, France 2.Claude Bernard Univ Lyon 1, Lyon, France 3.BC Canc, Dept Med Oncol, Vancouver, BC, Canada 4.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China 5.Queen Mary Hosp, Hong Kong, Peoples R China 6.ASST Papa Giovanni XXIII, Bergamo, Italy 7.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China 8.Azienda Osped Santa Maria Terni, Terni, Italy 9.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China 10.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 11.Shanghai Jiao Tong Univ, Xin Hua Hosp, Sch Med, Shanghai, Peoples R China 12.Fujian Med Univ, Fujian Inst Hematol, Union Hosp, Fuzhou, Peoples R China 13.Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China 14.Osped Maggiore Parma, Ematol Ctr Trapianti Midollo Osseo CTMO, Parma, Italy 15.Tianjin Med Univ, Canc Inst Hosp, Tianjin, Peoples R China 16.Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China 17.Sichuan Univ, West China Hosp, Chengdu, Peoples R China 18.Beijing Hosp, Beijing, Peoples R China 19.Beigene Co Ltd, Shanghai, Peoples R China 20.Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy
推荐引用方式 GB/T 7714	Bachy, Emmanuel,Savage, Kerry J.,Huang, Huiqiang,et al. Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Bachy, Emmanuel.,Savage, Kerry J..,Huang, Huiqiang.,Kwong, Yok-Lam.,Gritti, Giuseppe.,...&Zinzani, Pier Luigi.(2022).Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Bachy, Emmanuel,et al."Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.".JOURNAL OF CLINICAL ONCOLOGY 40(2022).